Developer docs
API playgroundTry for free, no card

Search company profiles

PHARMA JAPAN

Full company profile

uuid00542p2

Namestring
PHARMA JAPAN
Legal namestring
JIHO, Inc.
Websiteurl
pj.jiho.jp
Company typeenum
Private
Founded yearint
2001
Descriptiontext

PHARMA JAPAN is an English-language subscription news service covering Japan's pharmaceutical industry, operated by JIHO, Inc., a Japanese media company headquartered in Chiyoda-ku, Tokyo. The service was launched in 2001 to translate and repackage content from Nikkan Yakugyo, JIHO's flagship Japanese-language pharma trade journal, addressing a documented gap in authoritative English-language coverage of Japan's drug pricing, regulatory, and reimbursement landscape.

The product is a single subscription-based digital publication delivered via the website pj.jiho.jp, organized into editorial categories (Regulatory, Business, Organization, Academia, Commentary, Column, Trends, Feature, Interview, Lexicon). Coverage spans Chuikyo drug pricing reforms, MHLW safety actions, FDA/Japan regulatory interaction, M&A activity, regenerative medicine policy, and clinical development, including exclusive interviews with top regulatory officials. An eBook format accessible via Adobe Reader is available to subscribers as an additional consumption surface.

Monetization is purely subscription-based. Annual full subscriber access is priced at 180,000 yen per ID (excluding tax), with a 6-month option at 94,800 yen and volume discounts offered for 5+ user corporate packages via inquiry. A 2-week free trial and a free "Today's Headlines" daily email digest serve as top-of-funnel acquisition channels. The publication is targeted at pharmaceutical executives, regulatory affairs specialists, R&D personnel, and business development leaders working in or with interest in Japan's pharma sector, including English-speaking professionals outside Japan. Headcount is approximately 6 employees, consistent with a lean editorial operation.

Short descriptiontext

PHARMA JAPAN is an English-language subscription news service covering Japan's pharmaceutical industry, operated by JIHO, Inc. It translates content from Nikkan Yakugyo and serves pharmaceutical executives, regulatory affairs specialists, and R&D leaders needing English coverage of Japan's drug pricing, regulatory, and reimbursement landscape.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
Markets served

Serves global market

Keyword5 values
pharmaceutical industry news, regulatory intelligence, drug pricing coverage, pharma trade publication, medical policy reporting
NAICS code1 code
  • Periodical Publishers513120
SIC code1 code
  • Periodicals: Publishing Or Publishing & Printing2721
Product category
Pharmaceutical Industry News & Trade Publication
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Subscription Revenue
TypeSubscription Recurring
Description

PHARMA JAPAN generates revenue primarily through paid subscriptions. Full Subscriber plans are offered at 180,000 yen per ID per year (excluding tax) or 94,800 yen for 6 months. Volume discounts are available for 5 or more users under combined billing. Free tiers include a 2-week trial and a no-cost Today's Headlines email notice.

pj.jiho.jp
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Personnel, Operations, Technology or R&D, Marketing or Sales
Pricing details4 tiers
1Full Subscriber — Annual
ModelSubscriptionBilling cadenceAnnual
Notes

180,000 yen per ID per year (excluding tax). Provides unlimited access to all news articles and website functions.

pj.jiho.jp
2Full Subscriber — 6 months
ModelSubscriptionBilling cadenceMulti-year contract
Notes

94,800 yen per ID per 6 months (excluding tax). Unlimited access to all news articles and website functions.

pj.jiho.jp
3Trial Subscriber — Free
ModelFreemiumBilling cadencePay-as-you-go
Notes

Free 2-week trial with unlimited access to all news articles and functions.

pj.jiho.jp
4Today's Headlines Subscriber — Free
ModelFreemiumBilling cadencePay-as-you-go
Notes

Free email notification of daily headlines and weekly news ranking.

pj.jiho.jp
GTM typeB2B
B2B
Offering typeDigital Commerce or Conte…
Digital Commerce or Content
Core offering1 text field

PHARMA JAPAN is an English-language subscription news service covering Japan's pharmaceutical industry, providing in-depth reporting on drug pricing, regulatory decisions (MHLW, Chuikyo), R&D trends, M&A, and pharmaceutical policymaking. All content is translated from Nikkan Yakugyo, a leading Japanese-language pharma trade journal also operated by JIHO, Inc. The publication is sold via paid subscriptions (Full Subscriber plans) with a free 2-week trial and a complimentary Today's Headlines email digest.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

PHARMA JAPAN is a single subscription-based English-language news publication covering Japan's pharmaceutical industry. The service provides regulatory, business, and R&D news, drug pricing updates, and pharmaceutical policymaking coverage, including exclusive interviews with top regulatory officials and pharma executives. Content is sourced from Nikkan Yakugyo and offered through tiered subscriptions (Full Subscriber, Trial Subscriber, and Today's Headlines Subscriber).

Product and service3 records
1PHARMA JAPAN Subscription News Service
CategoryPharmaceutical Industry News / Trade Publication
Description

English-language subscription news service providing coverage of Japan's pharmaceutical industry, including regulatory decisions, drug pricing and reimbursement policy, R&D trends, M&A activity, and industry developments. All content is translated from Nikkan Yakugyo and accessible via the pj.jiho.jp website through authenticated subscriber login.

2Today's Headlines Email Digest
CategoryEmail Newsletter / Lead Generation
Description

Free email notification service delivering daily pharmaceutical industry headlines and weekly news rankings from Japan to subscribers.

3PHARMA JAPAN eBook
CategoryDigital Content / eBook
Description

Subscriber-only eBook format of the PHARMA JAPAN publication, accessible via Adobe Reader through the website for full subscribers.

Scale indicator1 record

Each record includes

Type, Value, Description, Source

Partnership2 partners
Strategic tierMinorTypeChannel Partner/ Reseller/ Distributor
Description

Santen Pharmaceutical and Kyorin Pharmaceutical entered a co-promotion agreement in Japan for Alesion Eyelid Cream 0.5% (epinastine), a long-acting treatment for allergic conjunctivitis. Under the pact, Kyorin began promoting the product to targeted physicians. This is a co-promotion arrangement within the Japanese pharmaceutical market.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

FRONTEO built an AI prediction model with Daiichi Sankyo that automatically extracts toxicological interpretations from Standard for Exchange of Nonclinical Data (SEND) datasets and toxicity study reports. The model is powered by FRONTEO's AI technology. This is a co-development arrangement for an AI-driven drug discovery tool.

Recent move5 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Subscription-supported B2B news outlet covering biotech and pharma R&D, business, and policy. Comparable as a paid trade publication serving pharma/biotech industry professionals.

2Scrip (Citeline, Informa)
TypeDirect peer
Description

Pharma industry intelligence publication covering business, R&D, and policy globally under Informa's Citeline. Comparable business model (paid B2B pharma news/intelligence) and overlapping audience of pharma executives.

3FiercePharma
TypeDirect peer
Description

B2B pharma industry news outlet covering drug commercialization, regulatory, and policy. Comparable as a trade news brand serving pharma executives and industry professionals, though US-centric.

TypeDirect peer
Description

Subscription-based B2B intelligence publication covering biotech strategy, R&D, and policy. Comparable as a paid trade intelligence service for pharma/biotech industry professionals.

5Pharmaceutical Technology
TypeDirect peer
Description

B2B trade publication covering pharmaceutical manufacturing, R&D, and regulation. Comparable as a paid trade media brand serving pharma industry professionals with regulatory and business coverage.

6The Pharma Letter
TypeDirect peer
Description

Subscription-based B2B pharmaceutical trade publication covering global drug development, regulation, and pricing. Most comparable as a paid trade-news service targeting pharma professionals, though with broader global scope rather than Japan-specific focus.

TypeBroad incumbent
Description

Large incumbent pharma intelligence portfolio (parent of Pink Sheet, Scrip, Citeline, Trialtrove). Comparable as a broad pharma intelligence offering, but at significantly larger scale and broader scope than PHARMA JAPAN's Japan-focused niche.

8Pharma Japan (Jiho English) parent: JIHO / Nikkan Yakugyo
TypeOthers
Description

Nikkan Yakugyo, the Japanese-language sister publication from JIHO, Inc., is the underlying content source for PHARMA JAPAN. Included as an ecosystem participant rather than a true external peer — illustrates the content-pipeline relationship.

9DIA Global Forum
TypeEmerging player
Description

Regulatory-focused publication from the Drug Information Association covering global drug development and regulatory science. Comparable as a specialized pharma regulatory publication serving industry professionals, though distributed via association membership.

10Pink Sheet (Citeline, Informa)
TypeDirect peer
Description

Long-running pharma regulatory and policy intelligence publication, now part of Informa's Citeline. Directly comparable as a paid pharma regulatory/policy intelligence service for industry professionals.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

PHARMA JAPAN

Pharmaceutical Industry News & Trade Publicationpj.jiho.jp

PHARMA JAPAN is an English-language subscription news service covering Japan's pharmaceutical industry, operated by JIHO, Inc. It translates content from Nikkan Yakugyo and serves pharmaceutical executives, regulatory affairs specialists, and R&D leaders needing English coverage of Japan's drug pricing, regulatory, and reimbursement landscape.

What PHARMA JAPAN does

PHARMA JAPAN is an English-language subscription news service covering Japan's pharmaceutical industry, operated by JIHO, Inc., a Japanese media company headquartered in Chiyoda-ku, Tokyo. The service was launched in 2001 to translate and repackage content from Nikkan Yakugyo, JIHO's flagship Japanese-language pharma trade journal, addressing a documented gap in authoritative English-language coverage of Japan's drug pricing, regulatory, and reimbursement landscape.

The product is a single subscription-based digital publication delivered via the website pj.jiho.jp, organized into editorial categories (Regulatory, Business, Organization, Academia, Commentary, Column, Trends, Feature, Interview, Lexicon). Coverage spans Chuikyo drug pricing reforms, MHLW safety actions, FDA/Japan regulatory interaction, M&A activity, regenerative medicine policy, and clinical development, including exclusive interviews with top regulatory officials. An eBook format accessible via Adobe Reader is available to subscribers as an additional consumption surface.

Monetization is purely subscription-based. Annual full subscriber access is priced at 180,000 yen per ID (excluding tax), with a 6-month option at 94,800 yen and volume discounts offered for 5+ user corporate packages via inquiry. A 2-week free trial and a free "Today's Headlines" daily email digest serve as top-of-funnel acquisition channels. The publication is targeted at pharmaceutical executives, regulatory affairs specialists, R&D personnel, and business development leaders working in or with interest in Japan's pharma sector, including English-speaking professionals outside Japan. Headcount is approximately 6 employees, consistent with a lean editorial operation.

PHARMA JAPAN firmographics

Firmographics
Name
PHARMA JAPAN
Legal name
JIHO, Inc.
Website
https://pj.jiho.jp
Company type
Private
Founded year
2001
Operating status
Operating
Headcount range
1–10 employees
Short description
PHARMA JAPAN is an English-language subscription news service covering Japan's pharmaceutical industry, operated by JIHO, Inc. It translates content from Nikkan Yakugyo and serves pharmaceutical executives, regulatory affairs specialists, and R&D leaders needing English coverage of Japan's drug pricing, regulatory, and reimbursement landscape.
Ownership category
akta.pro rank

PHARMA JAPAN business model

Business model
GTM type
B2B
Offering type
Digital Commerce or Content
Cost components
Personnel, Operations, Technology or R&D, Marketing or Sales

Revenue model

  1. Subscription Revenue: PHARMA JAPAN generates revenue primarily through paid subscriptions. Full Subscriber plans are offered at 180,000 yen per ID per year (excluding tax) or 94,800 yen for 6 months. Volume discounts are available for 5 or more users under combined billing. Free tiers include a 2-week trial and a no-cost Today's Headlines email notice.

Pricing tiers

ModelBillingPrice
SubscriptionAnnualFull Subscriber — Annual
SubscriptionMulti-year contractFull Subscriber — 6 months
FreemiumPay-as-you-goTrial Subscriber — Free
FreemiumPay-as-you-goToday's Headlines Subscriber — Free

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

PHARMA JAPAN product offering

Product offering

Core offering

PHARMA JAPAN is an English-language subscription news service covering Japan's pharmaceutical industry, providing in-depth reporting on drug pricing, regulatory decisions (MHLW, Chuikyo), R&D trends, M&A, and pharmaceutical policymaking. All content is translated from Nikkan Yakugyo, a leading Japanese-language pharma trade journal also operated by JIHO, Inc. The publication is sold via paid subscriptions (Full Subscriber plans) with a free 2-week trial and a complimentary Today's Headlines email digest.

Product overview

PHARMA JAPAN is a single subscription-based English-language news publication covering Japan's pharmaceutical industry. The service provides regulatory, business, and R&D news, drug pricing updates, and pharmaceutical policymaking coverage, including exclusive interviews with top regulatory officials and pharma executives. Content is sourced from Nikkan Yakugyo and offered through tiered subscriptions (Full Subscriber, Trial Subscriber, and Today's Headlines Subscriber).

Differentiator

Problem solved

Functional benefit

Products and services

  • PHARMA JAPAN Subscription News Service English-language subscription news service providing coverage of Japan's pharmaceutical industry, including regulatory decisions, drug pricing and reimbursement policy, R&D trends, M&A activity, and industry developments. All content is translated from Nikkan Yakugyo and accessible via the pj.jiho.jp website through authenticated subscriber login.
  • Today's Headlines Email Digest Free email notification service delivering daily pharmaceutical industry headlines and weekly news rankings from Japan to subscribers.
  • PHARMA JAPAN eBook Subscriber-only eBook format of the PHARMA JAPAN publication, accessible via Adobe Reader through the website for full subscribers.

Companies that use PHARMA JAPAN

Customer profile

Segments1 record

Ideal customer profiles1 record

PHARMA JAPAN technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

PHARMA JAPAN partnerships and signals

Strategic signal

Partnerships

Two partnerships are on record, tiered minor.

  • Kyorin PharmaceuticalminorChannel Partner/ Reseller/ DistributorSanten Pharmaceutical and Kyorin Pharmaceutical entered a co-promotion agreement in Japan for Alesion Eyelid Cream 0.5% (epinastine), a long-acting treatment for allergic conjunctivitis. Under the pact, Kyorin began promoting the product to targeted physicians. This is a co-promotion arrangement within the Japanese pharmaceutical market.
  • Daiichi SankyominorStrategic or Co-development PartnerFRONTEO built an AI prediction model with Daiichi Sankyo that automatically extracts toxicological interpretations from Standard for Exchange of Nonclinical Data (SEND) datasets and toxicity study reports. The model is powered by FRONTEO's AI technology. This is a co-development arrangement for an AI-driven drug discovery tool.

Scale indicators1 record

Recent moves5 records

Expansion highlights5 records

PHARMA JAPAN competitors and assessment

Company assessment

Direct peers

  • Endpoints News: Subscription-supported B2B news outlet covering biotech and pharma R&D, business, and policy. Comparable as a paid trade publication serving pharma/biotech industry professionals.
  • Scrip (Citeline, Informa): Pharma industry intelligence publication covering business, R&D, and policy globally under Informa's Citeline. Comparable business model (paid B2B pharma news/intelligence) and overlapping audience of pharma executives.
  • FiercePharma: B2B pharma industry news outlet covering drug commercialization, regulatory, and policy. Comparable as a trade news brand serving pharma executives and industry professionals, though US-centric.
  • BioCentury: Subscription-based B2B intelligence publication covering biotech strategy, R&D, and policy. Comparable as a paid trade intelligence service for pharma/biotech industry professionals.
  • Pharmaceutical Technology: B2B trade publication covering pharmaceutical manufacturing, R&D, and regulation. Comparable as a paid trade media brand serving pharma industry professionals with regulatory and business coverage.
  • The Pharma Letter: Subscription-based B2B pharmaceutical trade publication covering global drug development, regulation, and pricing. Most comparable as a paid trade-news service targeting pharma professionals, though with broader global scope rather than Japan-specific focus.
  • Pink Sheet (Citeline, Informa): Long-running pharma regulatory and policy intelligence publication, now part of Informa's Citeline. Directly comparable as a paid pharma regulatory/policy intelligence service for industry professionals.

Broad incumbents

  • Informa Pharma Intelligence: Large incumbent pharma intelligence portfolio (parent of Pink Sheet, Scrip, Citeline, Trialtrove). Comparable as a broad pharma intelligence offering, but at significantly larger scale and broader scope than PHARMA JAPAN's Japan-focused niche.

Others

  • Pharma Japan (Jiho English) parent: JIHO / Nikkan Yakugyo: Nikkan Yakugyo, the Japanese-language sister publication from JIHO, Inc., is the underlying content source for PHARMA JAPAN. Included as an ecosystem participant rather than a true external peer — illustrates the content-pipeline relationship.

Emerging players

  • DIA Global Forum: Regulatory-focused publication from the Drug Information Association covering global drug development and regulatory science. Comparable as a specialized pharma regulatory publication serving industry professionals, though distributed via association membership.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks6 records

Key highlights6 records

Customer concentration

PHARMA JAPAN social profiles

Digital presence

PHARMA JAPAN financial estimates

Financial estimate

Revenue estimate

Valuation estimate

PHARMA JAPAN leadership team

Management profile

Number of profiles

PHARMA JAPAN funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

PHARMA JAPAN M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about PHARMA JAPAN

What does PHARMA JAPAN do?

PHARMA JAPAN is an English-language subscription news service covering Japan's pharmaceutical industry, providing in-depth reporting on drug pricing, regulatory decisions (MHLW, Chuikyo), R&D trends, M&A, and pharmaceutical policymaking. All content is translated from Nikkan Yakugyo, a leading Japanese-language pharma trade journal also operated by JIHO, Inc. The publication is sold via paid subscriptions (Full Subscriber plans) with a free 2-week trial and a complimentary Today's Headlines email digest.

Is PHARMA JAPAN a public or private company?

PHARMA JAPAN is a private company. It is classified as unknown and is currently operating.

When was PHARMA JAPAN founded?

PHARMA JAPAN was founded in 2001. It employs 1 to 10 people.

How does PHARMA JAPAN make money?

One revenue line is on record: subscription Revenue.

Who are PHARMA JAPAN's main competitors?

Direct peers on record are Endpoints News, Scrip (Citeline, Informa), FiercePharma, BioCentury, Pharmaceutical Technology, The Pharma Letter and Pink Sheet (Citeline, Informa). Informa Pharma Intelligence is listed as a broad incumbent. Pharma Japan (Jiho English) parent: JIHO / Nikkan Yakugyo is listed as an others. DIA Global Forum is listed as an emerging player.

Does PHARMA JAPAN have an API?

No public API is recorded for PHARMA JAPAN.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales